Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVATAR study
2024-518577-34-00Phase 4Completed
- Sponsor
- University of Rome Tor Vergata
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tofacitinib in autoimmune colitis, sponsored by University of Rome Tor Vergata. Primary endpoint: Immunological characterization. Started Nov 2024; status: completed.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2024-518577-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518577-34-00.